Project no.: HIV-NAT 169
A randomised, open label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV 1 infected individuals with stable, well controlled plasma HIV RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART)
Publications:
- J Clin Microbiol. 2013;51(7):2063-71.
- J Clin Microbiol. 2013;51(12):4287.
